Belladonna/caffeine/ergotamine/pentobarbital and Alcohol/Food Interactions
There are 14 alcohol/food/lifestyle interactions with belladonna / caffeine / ergotamine / pentobarbital.
Pentobarbital Alcohol (Ethanol)
Major Drug Interaction
Ask your doctor before using PENTobarbital together with ethanol (alcohol), this can add to dizziness, drowsiness and other side effects of PENTobarbital. Be careful if you drive or do activities that require you to be awake and alert. Talk with your doctor before using any medications together, or drinking alcohol with PENTobarbital. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Ergotamine Alcohol (Ethanol)
Moderate Drug Interaction
PENTobarbital may reduce the blood levels and effects of ergotamine. Contact your doctor if your symptoms worsen or your condition changes during treatment with these medications. Your doctor may be able to prescribe alternatives that do not interact, or you may need a dose adjustment or more frequent monitoring to safely use both medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Belladonna Alcohol (Ethanol)
Moderate Drug Interaction
Ask your doctor before using belladonna together with ethanol (alcohol). Use alcohol cautiously. Alcohol may increase drowsiness and dizziness while you are taking belladonna. You should be warned not to exceed recommended dosages and to avoid activities requiring mental alertness. If your doctor prescribes these medications together, you may need a dose adjustment to safely take this combination. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Ergotamine Nicotine
Moderate Drug Interaction
Nicotine may increase the effects of ergotamine in narrowing the blood vessels and decreasing blood flow. A severe decrease in blood flow to the brain and other parts of the body can lead to dangerous side effects. Contact your doctor immediately if you experience coldness, paleness, discoloration, numbness, tingling, or pain in your hands or feet; muscle pain or weakness; severe or worsening headache; blurred vision; severe abdominal pain; chest pain; or shortness of breath while using these medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Ergotamine Nicotine
Moderate Drug Interaction
PENTobarbital may reduce the blood levels and effects of ergotamine. Contact your doctor if your symptoms worsen or your condition changes during treatment with these medications. Your doctor may be able to prescribe alternatives that do not interact, or you may need a dose adjustment or more frequent monitoring to safely use both medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Nicotine Caffeine
Minor Drug Interaction
Information for this minor interaction is available on the professional version.
Ergotamine Food
Moderate Food Interaction
Consumer information for this interaction is not currently available.
MONITOR: Grapefruit juice may increase the plasma concentrations of orally administered drugs that are substrates of the CYP450 3A4 isoenzyme. The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit. Because grapefruit juice inhibits primarily intestinal rather than hepatic CYP450 3A4, the magnitude of interaction is greatest for those drugs that undergo significant presystemic metabolism by CYP450 3A4 (i.e., drugs with low oral bioavailability). In general, the effect of grapefruit juice is concentration-, dose- and preparation-dependent, and can vary widely among brands. Certain preparations of grapefruit juice (e.g., high dose, double strength) have sometimes demonstrated potent inhibition of CYP450 3A4, while other preparations (e.g., low dose, single strength) have typically demonstrated moderate inhibition. Pharmacokinetic interactions involving grapefruit juice are also subject to a high degree of interpatient variability, thus the extent to which a given patient may be affected is difficult to predict.
MANAGEMENT: Patients who regularly consume grapefruit or grapefruit juice should be monitored for adverse effects and altered plasma concentrations of drugs that undergo significant presystemic metabolism by CYP450 3A4. Grapefruit and grapefruit juice should be avoided if an interaction is suspected. Orange juice is not expected to interact with these drugs.
Caffeine Food
Minor Food Interaction
Information for this minor interaction is available on the professional version.
Switch to professional interaction data
Pentobarbital High Blood Pressure (Hypertension)
Major Potential Hazard, Moderate plausibility
barbiturates IV - cardiovascular
The intravenous administration of barbiturates may produce severe cardiovascular reactions such as bradycardia, hypertension, or vasodilation with fall in blood pressure, particularly during rapid infusion. Parenteral therapy with barbiturates should be administered cautiously in patients with hypertension, hypotension, or cardiac disease. The intravenous administration of barbiturates should be reserved for emergency treatment of acute seizures or for anesthesia.
Caffeine High Blood Pressure (Hypertension)
Major Potential Hazard, Moderate plausibility
CNS stimulants - cardiac disease
Many CNS stimulants are contraindicated in patients with significant cardiovascular impairment such as uncompensated heart failure, severe coronary disease, severe hypertension (including that associated with hyperthyroidism or pheochromocytoma), cardiac structural abnormalities, serious arrhythmias, etc. Sudden death has been reported in patients with structural cardiac abnormalities or other serious cardiac disease who are treated with CNS stimulants at the recommended dosages for attention deficit hyperactivity disorder; use of these agents should be avoided in patients with known structural cardiac abnormalities, cardiomyopathy, serious cardiac arrhythmia, coronary artery disease, or other serious cardiac disease. Additionally, stroke, myocardial infarction, chest pain, syncope, arrhythmias, and other symptoms have been reported in adults under treatment. A careful assessment of the cardiovascular status should be done in patients being considered for treatment. This includes family history, physical exam, and further cardiac evaluation (EKG and echocardiogram). Patients who develop symptoms should have a detailed cardiac evaluation and if needed, treatment should be suspended.
Caffeine High Blood Pressure (Hypertension)
Major Potential Hazard, Moderate plausibility
CNS stimulants - hypertension
CNS stimulants increase blood pressure and heart rate; the use of some agents may be contraindicated in patients with severe/uncontrolled hypertension. Caution should be used when administering to patients with preexisting high blood pressure (even mild hypertension) and other cardiovascular conditions. All patients under treatment should be regularly monitored for potential tachycardia and hypertension.
Ergotamine High Blood Pressure (Hypertension)
Major Potential Hazard, High plausibility
ergot alkaloids - vasospastic reactions
The use of ergot alkaloids is contraindicated in patients with conditions predisposing them to vasospastic reactions, including, ischemic heart disease (angina, history of myocardial infarction, silent ischemia), peripheral vascular disease, sepsis, shock, vascular surgery, uncontrolled hypertension, and severely impaired hepatic or renal function. The vasoconstriction produced be ergot alkaloids may exacerbate these conditions. Ergot alkaloids may cause vasospastic reactions other than coronary artery vasospasm such as peripheral vascular reactions, and colonic ischemia, causing muscle pains, numbness, coldness, pallor, and cyanosis of the digits. In patients with compromised circulation, persistent vasospasm may result in gangrene or death. Nitroprusside and heparin have been used to treat ergotamine- induced severe vasoconstriction.
Caffeine High Blood Pressure (Hypertension)
Moderate Potential Hazard, Moderate plausibility
caffeine - cardiotoxicity
Like other methylxanthines, caffeine at high dosages may be associated with positive inotropic and chronotropic effects on the heart. Caffeine may also produce an increase in systemic vascular resistance, resulting in elevation of blood pressure. Therapy with products containing caffeine should be administered cautiously in patients with severe cardiac disease, hypertension, hyperthyroidism, or acute myocardial injury. Some clinicians recommend avoiding caffeine in patients with symptomatic cardiac arrhythmias and/or palpitations and during the first several days to weeks after an acute myocardial infarction.
Belladonna High Blood Pressure (Hypertension)
Minor Potential Hazard, Low plausibility
anticholinergics - hypertension
Cardiovascular effects of anticholinergics may exacerbate hypertension. Therapy with anticholinergic agents should be administered cautiously in patients with hypertension.
Switch to professional interaction data
Belladonna/caffeine/ergotamine/pentobarbital drug interactions
There are 854 drug interactions with belladonna / caffeine / ergotamine / pentobarbital.
Belladonna/caffeine/ergotamine/pentobarbital disease interactions
There are 43 disease interactions with belladonna / caffeine / ergotamine / pentobarbital which include:
- cardiovascular adverse effects
- autonomic neuropathy
- GI obstruction
- glaucoma
- obstructive uropathy
- reactive airway diseases
- myasthenia gravis
- infectious diarrhea
- acute alcohol intoxication
- drug dependence
- liver disease
- porphyria
- rash
- respiratory depression
- cardiovascular
- prolonged hypotension
- cardiac disease
- hypertension
- psychiatric disorders
- vasospastic reactions
- PUD
- cardiac disease
- tachycardia
- coronary artery disease
- gastric ulcer
- gastroesophageal reflux
- ulcerative colitis
- liver disease
- renal failure
- adrenal insufficiency
- depression
- hematologic toxicity
- osteomalacia
- paradoxical reactions
- cardiotoxicity
- liver disease
- renal dysfunction
- seizure disorders
- GERD
- hypertension
- hyperthyroidism
- diarrhea
- fever
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.